PDCD1 and melanoma: In an open-label phase III trial, 168 patients (86% with anti-PD-1-refractory disease) with unresectable stage IIIC-IV melanoma (AJCC7 criteria) were randomised 1 : 1 to receive either TILs (manufactured at each trial centre) or ipilimumab.